Crohn's Disease

Maintenance therapy with Skyrizi boosted clinical and endoscopic outcomes in patients with Crohn’s disease, according to a presentation at the Congress of European Crohn’s and Colitis Organization.

Successful management of Crohn’s perianal fistulas relies on adequate abscess drainage and controlled healing, according to a presenter at the GUILD conference 2022.

IV risankizumab followed by maintenance therapy induced sustained improvement in endoscopic outcomes in patients with moderate to severe Crohn’s disease, according to research presented at ECCO.

Skyrizi was effective and well tolerated during induction and maintenance therapy in patients with moderate to severe Crohn’s disease, according to two presentations at the Congress of the European Crohn’s and Colitis Organization.

Anti-tumor necrosis factor induction paired with surgical closure correlated with better long-term outcomes and decreased recurrence in patients with Crohn’s perianal fistulas, according to presented research.

The proteomic profile of breast milk of women with inflammatory bowel disease may affect an infant’s microbiome development and fecal calprotectin, according to a presenter at the Congress of the European Crohn’s and Colitis Organization.

Patients with Crohn’s disease who stopped infliximab had a significantly higher risk of relapse vs. those who continued combination therapy, according to results presented at the Congress of the European Crohn’s and Colitis Organization.

In this Healio video series, which focuses on cultural competency in the treatment of inflammatory bowel disease, Sumit Bhatia, MD, said many Indian patients do not accept diagnosis of the disease due to cultural stigmas.

Though further study is warranted, Leonard B. Weinstock, MD, FACP, adjunct professor at the Washington University School of Medicine, reported promising results of low-dose naltrexone use among two patients with Crohn’s disease.

Regardless of immunosuppression medication status, most patients with inflammatory bowel disease mounted a high-positive antibody response to the standard SARS-CoV-2 vaccination regimen, according to research.